Ticker LaunchReverse merger · Completed · SER
Serina Therapeutics, Inc.
Reverse merger with AgeX Therapeutics, Inc.
Serina Therapeutics, Inc. merged into AgeX Therapeutics, Inc., a NYSE American biotech funded by a Juvenescence convertible note, in a reverse merger that takes the private company public. The deal was announced on Aug 29, 2023 and closed on Mar 26, 2024. The combined company trades as Serina Therapeutics, Inc. (SER) on NYSE American.
Serina Therapeutics is a clinical-stage biotechnology company developing therapies for Parkinson's disease and other neurological diseases. Its lead candidate SER-252, POZ-apomorphine, is in preclinical studies, with an IND submission for a Phase I trial planned for 2025.
- Status
- Completed
- Private company
- Serina Therapeutics, Inc.
- Public company
- AgeX Therapeutics, Inc.
- Public company business before
- NYSE American biotech funded by a Juvenescence convertible note
- Announced
- Aug 29, 2023
- Closed
- Mar 26, 2024
- Combined company
- Serina Therapeutics, Inc. (SER)
- Exchange
- NYSE American
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Apr 1, 2024
- Closing press release
- All filings on EDGAR CIK 1708599
Other completed reverse mergers
- Trawsfynydd Therapeutics, Inc.into Onconova Therapeutics, Inc. · Apr 1, 2024
- VinHMS Pte. Ltd.into Vemanti Group, Inc. · Apr 1, 2024
- Q32 Bio Inc.into Homology Medicines, Inc. · Mar 25, 2024
- LENZ Therapeutics (LENZ OpCo)into Graphite Bio, Inc. · Mar 21, 2024
- Emergent Health Corp.into Resonate Blends, Inc. · Mar 14, 2024
- XTI Aircraft Companyinto Inpixon · Mar 12, 2024